Prolonged Outcomes Following the Treatment of Restenosis in Drug-Eluting Stents

Background: Drug-eluting stents have significantly lowered the risk of restenosis. However, how to treat restenosis inside a DES is unknown. While the number of severe adverse cardiovascular events (MACE) linked to drug-eluting stents (DES) has significantly decreased, stent thrombosis (STH) and in-stent restenosis (ISR) continue to be significant clinical problems. Materials and Methods: This observation cohort study was conducted in the Department of Cardiology, Universal Medical College and Northeast Medical College, Sylhet. During study period 2016 to 2020 Universal Medical College and 2020 to 2022 Northeast Medical College. Among 509 lesions treated with DES, 26 required clinically driven revascularization for ISR. We identified 26 consecutive patients who developed ISR, among them Homo-Stents (n=17), Hetero-Stents (n=5) and (n=4) treated by other. Results: Three cases (75%) in the other ISR group and one (20%) in the hetero-stent group had a history of congestive heart failure. Of the three groups, only one had clinical characteristics that were statistically significant (p<0.05), whereas the other two did not (p>0.05). In the hospital, the differences between the three groups at six and twelve months were not statistically significant (p>0.05). Conclusion: There is a high long-term rate of MACE associated with current DES therapies for ISR or STH.